omniture
logo
Search

/DISREGARD RELEASE: YS Biopharma/

YS Biopharma
2023-12-21 05:15 2243

We are advised by YS Biopharma Co., Ltd. (NASDAQ:YS) that journalists and other readers should disregard the news release, "YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023", issued on December 20, 2023 by YS Biopharma over PR Newswire, as the release contained erroneous information.

Source: YS Biopharma
Related Stocks:
NASDAQ:YS
Media Room more

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

2024-04-19 19:00
3590

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

2024-04-18 20:00
1200

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

2024-04-16 20:00
1578

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

2024-04-09 20:00
1185

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

2024-04-03 20:00
1588

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

2024-03-05 21:00
2477
Related News

MGI Tech opens Customer Experience Center in Brazil to contribute to the advancement of genomics in Latin America

2024-04-28 17:54

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

2024-04-26 21:00
955

Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers

2024-04-26 21:00
997

Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa

2024-04-26 12:39
865

Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints

2024-04-26 01:25
936

2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor

2024-04-25 22:00
825
collection